Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Nov 26;10(11):e3635.
doi: 10.7759/cureus.3635.

Type II Renal Tubular Acidosis Secondary to Topiramate: A Review

Ankur Sinha  1 , Phone Oo  2 , Muhammad U Asghar  3 , Hira A Cheema  4 , Sanwal S Mehta  5 , Joshua C Leinwand  3 , Kalyana Janga  6
Affiliations
Review

Type II Renal Tubular Acidosis Secondary to Topiramate: A Review

Ankur Sinha et al. Cureus. .

Abstract

Topiramate (TMP) is a broad-spectrum anticonvulsant drug used to treat a wide variety of seizure disorders, for migraine prophylaxis, and for many other indications. An important side effect of TMP is metabolic acidosis, which is mediated by renal tubular defects. TMP inhibits carbonic anhydrase, an enzyme that is necessary for acid handling in the proximal renal tubule. Patients can present with asymptomatic serum electrolyte derangements, acute change in mental status, hyperventilation, cardiac arrhythmias, or other sequelae of metabolic acidosis and associated respiratory compensation. If taken chronically, TMP can cause renal stone formation, bone mineralization defects, and several other effects secondary to changes in serum and urine pH and electrolytes. There is no well-studied way to prevent metabolic acidosis in patients taking TMP, but physicians should be vigilant when prescribing this drug to patients with the history of renal diseases and other comorbidities, and aware of this potential etiology of metabolic acidosis. We present a literature review of the underlying mechanisms involved in the development of renal tubular acidosis secondary to TMP and its clinical consequences.

Keywords: renal tubular acidosis; topiramate.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Mechanisms of Action of Topiramate.
Figure 2
Figure 2. Development of Proximal Renal Tubular Acidosis.
See this image and copyright information in PMC

References

    1. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy. Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. French JA, Kanner AM, Bautista J, et al. Neurology. 2004;62:1261–1273. - PubMed
    1. Clinical efficacy of topiramate as add‐on therapy in refractory partial epilepsy: the European experience. Ben‐Menachem E. Epilepsia. 1997;38:0. - PubMed
    1. Food and Drug Administration (FDA). FDA labelling information. [Nov;2018 ];http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm 2018
    1. New and future migraine therapy. Ramadan NM, Buchanan TM. Pharmacol Ther. 2006;112:199–212. - PubMed
    1. Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Supuran CT, Di Fiore A, De Simone G. Expert Opin Emerg Drugs. 2008;13:383–392. - PubMed

LinkOut - more resources